Highlights
- •Social disadvantage may be present in diabetes complications in young adults.
- •Young men with non-Western origin were more likely to develop a complication.
- •Income was not associated with diabetes complication development.
- •Young adults with uncontrolled HbA1c were more likely to develop a complication.
- •Proactive treatment should focus on HbA1c regulation in all at-risk populations.
Abstract
Aims
Methods
Results
Conclusion
Keywords
1. Introduction
2. Materials and methods
2.1 Design and data sources
2.2 Study population
2.3 Primary outcome
2.4 Medical determinants
2.5 SDOH
2.6 Validation sample
2.7 Statistical analysis
3. Results
3.1 Baseline characteristics

First micro- or macrovascular complication | |||||
---|---|---|---|---|---|
Total (N = 761) | With complication (n = 154) | Without complication (n = 607) | |||
Social determinants of health | |||||
Age in years | 39 (33–42) | 40 (35–43) | 39 (33–42) | ||
Men, | 375 (49.3) | 97.8 (63.5) | 277.2 (45.7) | ||
Standardized household income Percentile 0–33 33–66 66–100 | 363.4 (47.8) 230.5 (30.3) 167.1 (22.0) | 74.9 (48.6) 55.2 (35.8) 24 (15.6) | 288.5 (47.5) 175.3 (28.9) 143.1 (23.6) | ||
Ethnicity group Dutch or Western origin Non-Western origin Origin Dutch or other Western Turkey Morocco South-Asian Other non-Western | 272.6 (37.4) 488.4 (64.2) 272.6 (35.8) 76 (10.0) 92.2 (12.1) 165.6 (21.8) 154.8(20.3) | 45.4 (29.5) 108.6 (70.5) 45.4 (29.5) 21 (13.6) 15 (9.7) 38.8 (25.2) 33.9 (22.0) | 227.2 (37.4) 379,8 (62,6) 227.2 (37.4) 55 (9.1) 77.2 (12.7) 126.8 (20.9) 120.9 (19.9) | ||
Medical determinants | |||||
Diabetes treatment class Lifestyle Oral blood glucose-lowering drugs Insulin and oral blood glucose-lowering drugs | 200 (26.3) 447 (58.7) 114 (15.0) | 33 (21.4) 97.5 (63.3) 23.6 (15.3) | 167 (27.5) 349.5 (57.6) 90.4 (14.9) | ||
Chronic comorbidity at diagnosis Of which: Hypertension Adiposity Mental illness Chronic neck and back pain Arthrosis Alcohol abuse | 296.5 (39.0) 104 (13.7) 71.7 (9.4) 79.1 (10.4) 45.6 (6.0) 11 (1.5) 12 (1.6) | 60.9 (39.5) 25(16.2) 14.1 (9.1) 10.1 (6.6) < 10 (< 6.5) < 10 (< 6.5) < 10 (< 6.5) | 235.6 (38.8) 78.9(13.0) 57.6(9.5) 69 (11.4) < 10 (<1.6) < 10 (<1.6) < 10 (<1.6) | ||
Complications diagnosis-specified Retinopathy Nephropathy Polyneuropathy Cerebrovascular incident/TIA Ischemic heart disease Peripheral artery disease Cardiovascular or diabetes-related death | 70 (9.2) 18 (2.4) 15 (2.0) 24 (3.2) 41 (5.4) < 10 (<1.5) < 10 (<1.5) | 70 (45.4) 18 (11.7) 15 (9.7) 24 (15.6) 41 (26.5) < 10 (<6.5) < 10 (<6.5) | n/a | ||
HbA1c mmol/mol % | 48.62 (43.20 −57.02) 6.6 (6.1–7.4) | 52.12 (45.24–64.38) 6.9 (6.3–8.0) | 47.55 (43.03–55.65) 6.5 (6.1–7.2) | ||
Poorly controlled HbA1c | 274 (36.0) | 74.7 (48.5) | 199.3 (32.8) | ||
BMI kg/ | 31.93 (6.18) | 31.32 (5.13) | 32.10 (6.43) | ||
Smoking Never Former Current | 286.2 (37.6) 95.7 (12.6) 379.1 (49.8) | 42.8 (27.8) 18.7 (12.1) 92.6 (60.1) | 243.4 (40.1) 77 (12.7) 286.5 (47.2) |
3.2 Validation sample
Study cohort 2010 (N = 127) | Validation sample 2010 (N = 622) | |
---|---|---|
Age (median ± IQR) | 38(33–42) | 39(33–42) |
men n (%) | 60(47.2) | 299(48.1) |
Diabetes treatment class n (%) Lifestyle Oral blood glucose-lowering drugs Insulin and oral blood glucose-lowering drugs | 36 (28.4) 76 (59.8)* 15(11.8) | N/A 550(88.4)* 72(11.6) |
Standardized household income n (%) 0–33 percentile 33–66 percentile 66–100 percentile Missing | 58 (45.7) 34 (26.8) 28 (22.0) 7 (5.5) | 283 (45.5) 195 (31.4) 133 (21.4) 12 (1.9) |
Ethnicity group n (%) Non-Western origin Origin Dutch or other Western Turkey Morocco South-Asian Other non-Western | 79 (62.2) 48 (37.8) 10 (7.9) 14 (11.0) 26 (20.5) 29 (22.8) | 434 (69.7) 188 (30.3) 83 (13.3) 55 (8.8) 146 (23.5) 150 (24.1) |
3.3 Predictors of complications
Main outcome | Sub-analysis | |||
---|---|---|---|---|
Model A: first micro OR macrovascular complication | Model B: first microvascular complication | Model C: first macrovascular complication | ||
Pooled data after MI (n = 761, complications = 154) Hazard ratio (95% CI) | Complete case analysis (n = 574, complications 154) Hazard ratio (95% CI) | Pooled data after MI (n = 761, complications = 98) Hazard ratio (95% CI) | Pooled data after MI (n = 761, complications = 72) Hazard ratio (95% CI) | |
SDOH | ||||
Sex (women) | 0.59 (0.41–0.84)* | 0.51 (0.30 – 0.88) * | 0.50 (0.31 – 0.79)* | 0.83 (0.50 – 1.38) |
Age (years) | 1.03 (1.00–1.06) | 1.02 (0.97 – 1.07) | 0.99 (0.96 −1.03) | 1.09 (1.03 – 1.15)* |
Standardized household income (Reference: 0–33 percentile) 33–66 percentile 66–100 percentile | 1.24 (0.86 – 1.79) 0.78 (0.47 – 1.28) | 1.18 (0.68 – 2.02) 0.94 (0.49 – 1.80) | 1.29 (0.80.−2.06) 1.12 (0.62 – 2.03) | 1.18 (0.70 – 1.97) 0.50 (0.23 −1.10) |
Ethnicity group Non-Western (reference: Western) | 1.29 (0.87 – 1.90) | 1.79 (0.96 −3.35) | 2.23 (1.34 – 3.71)* | 0.61 (0.37 – 1.00)* |
Medical determinants index year | ||||
Diabetes treatment class (reference: no medication) A10B medication Combination of A10B and A10A | 1.40 (0.93–2.11) 1.25 (0.70 – 2.22) | 1.43 (0.74 – 2.76) 0.72 (0.24 – 2.16) | 1.95 (1.08 – 3.52)* 2.38 (1.12 – 5.06)* | N/A N/A |
HbA1c> 7% (>53 mmol/mol) (reference HbA1c ≤7% (≤53 mmol/mol) | 1.72 (1.15 – 2.57)* | 2.67 (1.63 – 4.37)* | 1.76 (1.04 – 2.99)* | N/A |
Mean BMI | 1.00 (0.97 – 1.03) | 0.99 (0.95 – 1.04) | N/A | N/A |
Co-morbidity (yes) | 1.10 (0.78 – 1.54) | 0.81 (0.50 – 1.34) | N/A | N/A |
Smoking (reference: never) Former Current | 1.17 (0.59 – 2.35) 1.51 (0.98 – 2.31) | 1.53 (0.66 – 3.55) 1.75 (0.99 – 3.12) | 1.45 (0.61 – 3.47) 1.38 (0.79 – 2.39) | 1.04 (0.19 – 5.81)
|
*indicates statistically significant compared to reference category p < 0.05 † all displayed HR are adjusted for the effects of all other determinants in the model | ||||
Internal validation | ||||
C-index optimism-corrected (non-corrected) Calibration curve optimism-corrected ( non-corrected) Intercept Slope | 0.62 (0.64) 0.24 (0.054) 0.70 (0.95) | 0.66 (0.67) 0.26 (0.39) 0.73 (0.99) | 0.67 (0.68) 0.12 (−0.02) 0.86 (1.02) |
Hazard ratio (95%) (confidence interval) | ||||
---|---|---|---|---|
Men N = 375 n complications= 99 | p-value | Women N = 386 n complications= 58 | p-value | |
Age (years) | 1.04 (1.00–1.08) | 0.029 | 1.00 (0.96–1.05) | 0.945 |
HbA1c > 7% (>53 mmol/mol) (reference HbA1c ≤7% (≤53 mmol/mol) | 2.02 (1.291–3.156) | 0.002 | 1.59 (0.83–3.04) | 0.163 |
Ethnicity group Non-Western (reference: Western) | 1.98 (1.194–3.295) | 0.008 | 0.67 (0.38–1.18) | 0.164 |
Standardized household income (reference: 0–33 percentile) 33–66 percentile 66–100 percentile | 1.08 (0.68–1.736) 0.74 (0.40–1.36) | 0.737 0.331 | 1.54 (0.85–2.78) 0.80 (0.35–1.83) | 0.153 0.601 |
3.4 Sub-analyses
4. Discussion
4.1 Summary of the main findings
4.2 Strengths and limitations
Ethics approval
Funding
Contributorship statement
Conflict of interest statement
Acknowledgments
Data sharing statement
Appendix A. Supplementary material
Supplementary material
Supplementary material
Supplementary material
Supplementary material
Supplementary material
Supplementary material
References
- The global spread of type 2 diabetes mellitus in children and adolescents.J. Pediatr. 2005; 146: 693-700
- Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association.Diabetes Care. 2018; 41: 2648-2668
- Earlier onset of complications in youth with type 2 diabetes.Diabetes care. 2014; 37: 436-443
- Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses.Diabetologia. 2021; 64: 275-287
- Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA(1c) and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes.Diabetologia. 2020; 63: 1542-1553
- Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood.Jama. 2017; 317: 825-835
- Socioeconomic status is not associated with the delivery of care in people with diabetes but does modify HbA1c levels: an observational cohort study (Elzha-cohort 1).Int J. Clin. Pr. 2021; 75e13962
N.H.G. Diabetes mellitus type 2 (Vierde herziening) [Available from: https://www.nhg.org/standaarden/volledig/nhg-standaard-diabetes-mellitus-type-2.
- Impact of socioeconomic status and gender on glycaemic control, cardiovascular risk factors and diabetes complications in type 1 and 2 diabetes: a population based analysis from a Scottish region.Diabetes Metab. 2015; 41: 145-151
- Social determinants of health and diabetes: a scientific review.Diabetes Care. 2020;
- World Health Organisation About Social Determinants of Health [Available from: http://www.who.int/social_determinants/en.
- Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland.Diabetologia. 2015; 58: 716-725
Tatulashvili S., Fagherazzi G., Dow C., Cohen R., Fosse S., Bihan H. Socioeconomic inequalities and type 2 diabetes complications: A systematic review. Diabetes & metabolism. 2019.
- How to evaluate population management? Transforming the care continuum alliance population health guide toward a broadly applicable analytical framework.Health Policy. 2015; 119: 522-529
- Identification of major cardiovascular events in patients with diabetes using primary care data.BMC Health Serv. Res. 2016; 16: 110
- Extramural Academic Network of the Leiden University Medical Centre Data Warehouse [Available from: https://www.lumc.nl/org/campusdenhaag/projecten/gezond-en-gelukkig-den-haag/
- The System of social statistical datasets of Statistics Netherlands: an integral approach to the production of register-based social statistics.Stat. J. IAOS. 2014; 30: 411-424
- Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025.Ned. Tijdschr. voor Geneeskd. 2009; 153: A580
- Cost variation in diabetes care across Dutch care groups?.Health Serv. Res. 2017; 52: 93-112
- Coded diagnoses from general practice electronic health records are a feasible and valid alternative to self-report to define diabetes cases in research.Prim. Care Diabetes. 2021; 15: 234-239
- Multimorbidity and comorbidity in the Dutch population - data from general practices.BMC Public Health. 2012; 12: 715
- Distinct trajectories of HbA1c in newly diagnosed Type 2 diabetes from the DPV registry using a longitudinal group-based modelling approach.Diabet. Med. 2019; 36: 1468-1477
Solar O. IA. A conceptual framework for action on the social determinants of health. Social Determinants of Health Discussion Paper 2 (Policy and Practice). World Health Organization. 2010.
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N. Engl. J. Med. 2008; 358: 2560-2572
- Socioeconomic status and type 2 diabetes complications among young adult patients in Japan.PLoS One. 2017; 12 (e0176087-e.)
- Effect of socioeconomic status on mortality among people with type 2 diabetes: a study from the Scottish Diabetes Research Network Epidemiology Group.Diabetes care. 2011; 34: 1127-1132
- Towards better clinical prediction models: seven steps for development and an ABCD for validation.Eur. Heart J. 2014; 35: 1925-1931
- Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.Stat. Med. 1996; 15: 361-387
- Assessment of predictive performance in incomplete data by combining internal validation and multiple imputation.BMC Med Res Method. 2016; 16: 144
- Bootstrap inference when using multiple imputation.Stat. Med. 2018; 37: 2252-2266
- Prevalentie van diabetes mellitus en hart- en vaatziekten onder Turkse, Marokkaanse en autochtone Nederlanders.Ned. Tijdschr. voor Geneeskd. 2003; 147: 1362-1366
- Sex and gender: modifiers of health, disease, and medicine.Lancet. 2020; 396: 565-582
- Group UPDSU. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.
- Prevention of Cardiovascular Disease Guidelines for assessment and management of cardiovascular risk. World Health Organization. 2007.
- Strategies for handling missing data in electronic health record derived data.EGEMS. 2013; 1: 1035
Article info
Publication history
Publication stage
In Press Corrected ProofIdentification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy